Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: The aim of the study was to explore the optimal timing of gonadotropin initiation and the reasonable interval of luteinizing hormone (LH) level in the gonadotropin-releasing hormone antagonist (GnRH-A) protocol.

Methods: A retrospective cohort study was conducted to analyze the LH level in patients with different ovarian response treated in GnRH-A protocol in 1361 IVF/ICSI cycles. Ovarian response (including AMH, AFC) in these patients were divided into the poor ovarian response group (an antral follicle count (AFC) ≤ 6, n = 394), the normal ovarian response group (an AFC > 6 and < 15, n = 570), and the high ovarian response group (an AFC ≥ 15, n = 397), according to the AFC. The patients were sub-grouped according to LH levels on the protocol initiation day, and the clinical outcomes (including dose of Gn initiation, Gn administration days, GnRH-ant administration days, P levels on the HCG day, E2 levels on the HCG day, LH levels on the HCG day, number of embryos transferred, total fertilization rate, embryo implantation rate (%), proportion of 2PN, proportion of good-quality embryos, endometrial thickness on the hCG injection day (mm), moderate to severe OHSS, AFC on the initiation day, proportion of type A endometrium on the hCG injection day, clinical pregnancy rate, biochemical pregnancy rate, early abortion rate, ectopic pregnancy rate) were compared.

Results: On the GnRH-A protocol initiation day, among all patients with different ovarian responses, the body mass index (BMI) in those with an LH ≥ 5 IU/L was lower. The difference of pregnancy outcome between the LH < 5 IU/L group and the LH ≥ 5 IU/L group were not statistically significant among the different ovarian response groups, but the LH < 5 IU/L group had a higher proportion of good-quality embryos (80.3 ± 24.9 vs. 74.8 ± 26.9, P =0.035) than the LH≥5IU/Lgroup in those with poor ovarian response. The total fertilization rate (82.2 ± 18.1 vs 85.4 ± 15.1, P =0.021) and proportion of two pronuclei (2PN) (69.0 ± 20.9 vs 72.7 ± 19.9, P =0.035) were higher in the LH ≥ 5 IU/L group than the LH<5 IU/L group for those with normal ovarian response. The embryo implantation rate (41.4 ± 41.3 vs 52.6 ± 43.4, P =0.012) was higher in the LH ≥ 5 IU/L group than in the LH<5 IU/L group in those with high ovarian response. The results of the multivariate logistic analysis showed that the age of the female partner, number of embryos transferred, proportion of good-quality embryos, endometrial thickness on the hCG injection day, and moderate-to-severe ovarian hyperstimulation syndrome (OHSS) were independent factors correlated with the outcome of live births (P < 0.05).

Conclusion: The LH levels on the gonadotropins (Gn) initiation day in GnRH-A protocol will not affect pregnancy outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.2174/0118715303281640240722070348DOI Listing

Publication Analysis

Top Keywords

ovarian response
28
initiation day
16
iu/l group
16
response group
12
levels hcg
12
hcg day
12
pregnancy rate
12
≥ iu/l
12
day
9
luteinizing hormone
8

Similar Publications

Background: Ovarian cancer (OC) remains the most lethal gynecological malignancy, largely due to its late-stage diagnosis and nonspecific early symptoms. Advances in biomarker identification and machine learning offer promising avenues for improving early detection and prognosis. This review evaluates the role of biomarker-driven ML models in enhancing the early detection, risk stratification, and treatment planning of OC.

View Article and Find Full Text PDF

Molecular impact of NOTCH signaling dysregulation on ovarian cancer progression, chemoresistance, and taxane response.

Biomed Pharmacother

September 2025

Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Laboratory of Pharmacogenomics, Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Electronic address:

Patients with epithelial ovarian cancer (EOC) face high mortality due to late diagnosis, recurrence, metastasis, and drug resistance. The NOTCH signaling pathway plays a critical role in cancer progression. This study analyzed NOTCH pathway deregulation in EOC patients and its response to taxane treatment in vitro and in vivo.

View Article and Find Full Text PDF

Ovarian cancer remains a major health threat with limited treatment options available. It is characterized by immunosuppressive tumor microenvironment (TME) maintained by tumor-associated macrophages (TAMs) hindering anti-tumor responses and immunotherapy efficacy. Here we show that targeting retinoblastoma protein (Rb) by disruption of its LxCxE cleft pocket causes preferential cell death in Rbhigh M2 polarized or M2-like Rbhigh immunosuppressive TAMs by induction of ER stress, p53 and mitochondria-related cell death pathways.

View Article and Find Full Text PDF

Aims: This review summarizes the role and future prospects of nuclear medicine in ovarian cancer, focusing on novel radiopharmaceuticals beyond FDG for diagnostic, predictive, and therapeutic applications within a theranostic framework.

Materials And Methods: A narrative literature review was conducted using major databases. Peer-reviewed articles addressing non-FDG radiopharmaceuticals in ovarian cancer were identified and assessed; FDG-based studies were excluded due to the availability of prior comprehensive reviews.

View Article and Find Full Text PDF

Objective: To present a case of metastatic endometrial carcinosarcoma (ECS) with a long-term complete response to chemotherapy using a paclitaxel and carboplatin regimen.

Case Report: A 47-year-old premenopausal woman was diagnosed with a large, advanced intrauterine tumor. She underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy.

View Article and Find Full Text PDF